



de Groot, N. M.S. et al. (2022) Critical appraisal of technologies to assess electrical activity during atrial fibrillation: a position paper from the European Heart Rhythm Association and European Society of Cardiology Working Group on eCardiology in collaboration with the Heart Rhythm Society, Asia Pacific Heart Rhythm Society, Latin American Heart Rhythm Society and Computing in Cardiology. *Europace*, 24(2), pp. 313-330. (doi: [10.1093/europace/euab254](https://doi.org/10.1093/europace/euab254)).

This is the Author Accepted Manuscript.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/261229/>

Deposited on: 25 January 2022

1 **Critical Appraisal of Technologies to Assess Electrical**

2 **Activity during Atrial Fibrillation**

3 *A Position Paper from the European Heart Rhythm Association and European Society of*
4 *Cardiology Working Group on eCardiology in collaboration with the Heart Rhythm Society,*
5 *Asia Pacific Heart Rhythm Society, Latin American Heart Rhythm Society and Computing in*
6 *Cardiology*

7 Natasja M.S. de Groot¹ (chair), Dipen Shah², Patrick M. Boyle³, Elad Anter⁴, Gari D. Clifford⁵,
8 Isabel Deisenhofer⁶, Thomas Deneke⁷, Pascal van Dessel⁸, Olaf Doessel⁹, Polychronis
9 Dilaveris¹⁰, Frank R. Heinzel¹¹, Suraj Kapa¹², Pier D. Lambiase¹³, Joost Lumens¹⁴, Pyotr G.
10 Platonov¹⁵, Tachapong Ngarmukos¹⁶, Juan Pablo Martinez¹⁷, Alejandro Olaya Sanchez¹⁸,
11 Yoshihide Takahashi¹⁹, Bruno P. Valdigem²⁰, Alle-Jan van der Veen²¹, Kevin Vernoooy²²,
12 Ruben Casado-Arroyo (co-chair)²³

13 ¹Department of Cardiology, Erasmus University Medical Centre, Rotterdam, Delft University
14 of Technology, Delft the Netherlands, ²Cardiology Service, University Hospitals Geneva,
15 Geneva, Switzerland, ³Department of Bioengineering, University of Washington, Seattle,
16 Washington, USA, ⁴Cardiac Electrophysiology Section, Department of Cardiovascular
17 Medicine, Cleveland Clinic, Cleveland, Ohio, USA,

18 ⁵Department of Biomedical Informatics, Emory University, Department of Biomedical
19 Engineering, Georgia Institute of Technology and Emory University, Atlanta, USA,

20 ⁶Department of Electrophysiology, German Heart Center Munich and Technical University of
21 Munich, Munich, Germany, ⁷Department of Cardiology, Rhon-klinikum Campus Bad
22 Neustadt, Germany, ⁸Department of Cardiology, Medisch Spectrum Twente, Twente, the
23 Netherlands, ⁹Karlsruher Institut für Technologie (KIT), Karlsruhe, Germany, ¹⁰1st University
24 Department of Cardiology, National & Kapodistrian University of Athens School of Medicine,

25 Hippokration Hospital, Athens, Greece, ¹¹Department of Internal Medicine and Cardiology,
26 Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum and DZHK (German Centre
27 for Cardiovascular Research), Berlin, Germany, ¹²Department of Cardiology, Mayo Clinic,
28 Rochester, USA, ¹³Barts Heart Centre and University College, London, UK, ¹⁴ Cardiovascular
29 Research Institute Maastricht (CARIM) Maastricht University, Maastricht, the Netherlands,
30 ¹⁵Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden, ¹⁶ Faculty of
31 Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ¹⁷Aragon Institute
32 of Engineering Research / IIS-Aragon and University of Zaragoza, Zaragoza, Spain, CIBER
33 Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Zaragoza, Spain,
34 ¹⁸Department of Cardiology, Hospital San José, Fundacion Universitaia de Ciencias de la Salud,
35 Bogota, Colombia, ¹⁹Department of Cardiovascular Medicine, Tokyo Medical and Dental
36 University, Tokyo, Japan, ²⁰ Department of Cardiology, Hospital Rede D'or São Luiz, hospital
37 Albert einstein and Dante pazzanese heart institute, São Paulo, Brasil, ²¹ Department Circuits
38 and Systems, Delft University of Technology, Delft, the Netherlands, ²²Department of
39 Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University
40 Medical Centre, Maastricht, the Netherlands, ²³Department of Cardiology, Erasme University
41 Hospital, Université Libre de Bruxelles, Brussels, Belgium.

42

43 **Word Count Manuscript:** 7780 words

44 **Journal:** *Europace*

45 **Address for correspondence**

46 Prof. Dr. N.M.S de Groot

47 Department of Cardiology

48 Unit Electrophysiology

49 RG 632/EE-1993

50 Erasmus Medical Centre

51 Doctor Molewaterplein 40

52 3015 GD Rotterdam, the Netherlands

53 Phone: +31-10-7035018

54 E-mail: n.m.s.degroot@erasmusmc.nl

55 1. Tom De Potter: OLV Aalst, Cardiology Department, Aalst, Belgium

56 2. Borislav Dinov: Herzzentrum Leipzig, Rhythmology Unit, Leipzig, Germany

57 3. Jędrzej Kosiuk: Helios Clinic Koethen, Department Of Electrophysiology, Koethen,
58 Germany

59 4. Dominik Linz: MUMC, Maastricht Hart en Vaat Centrum, Maastricht, the Netherlands

60 5. Lis Neubeck: Edinburgh Napier University

61 6. Emma Svennberg: Karolinska University Hospital, Cardiology Dept, Sweden & Dept
62 of Clinical Sciences, Danderyd's Hospital, Danderyd, Sweden

63 7. Young-Hoon Kim: Korea University Medical Center, Cardiology Department, Seoul,
64 Korea (Republic of)

65 8. Elaine Wan: Elaine Wan, Esther Aboodi Assistant Professor of Medicine, Director of
66 Electrophysiology Research, Cardiology and Cardiac Electrophysiology, Columbia
67 University, New York, USA

68 9. Nestor Lopez-Cabanillas: Adventist Cardiovascular Institute of Buenos Aires,
69 Argentina, Medical School, 8 College Road, Singapore

70 10. Emanuela T Locati: IRCCS Policlinico San Donato Department of Arrhythmology and
71 Electrophysiology, San Donato Milanese, Milan, Italy

72 11. Peter Macfarlane: University of Glasgow, Inst of Health and Wellbeing,
73 Electrophysiology Group, Level 1, New Lister Building, Royal Infirmary, Glasgow

74

75

76

77

78

79 **Abstract**

80 **Aims:** We aim to provide a critical appraisal of basic concepts underlying signal recording and
81 processing technologies applied for 1) AF mapping to unravel AF mechanisms and/or
82 identifying target sites for AF therapy and 2) AF detection, to optimize usage of technologies,
83 stimulate research aimed at closing knowledge gaps and developing ideal AF recording and
84 processing technologies.

85 **Methods:** Recording and processing techniques for assessment of electrical activity during AF
86 essential for diagnosis and guiding ablative therapy including body surface electrocardiograms
87 and endo- or epicardial electrograms (EGM) are evaluated.

88 **Results:** Discussion of 1) differences in uni-, bi- and multipolar (omnipolar/Laplacian)
89 recording modes, 2) impact of recording technologies on EGM morphology, 3) global or local
90 mapping using various types of EGM involving signal processing techniques including
91 isochronal-, voltage- fractionation-, dipole density-and rotor mapping, enabling derivation of
92 parameters like atrial rate, entropy, conduction velocity/direction, 4) value of epicardial and
93 optical mapping, 5) AF detection by cardiac implantable electronic devices containing various
94 detection algorithms applicable to stored EGMs, 6) contribution of machine learning to further
95 improvement of signals processing technologies.

96 **Conclusion:** Recording and processing of EGM (or ECG) are the cornerstones of (body
97 surface) mapping of AF. Currently available AF recording and processing technologies are
98 mainly restricted to specific applications or have technological limitations. Improvements in
99 AF mapping by obtaining highest fidelity source signals (e.g. catheter-electrode combinations)
100 for signal processing (e.g. filtering, digitization and noise elimination) is of utmost importance.
101 Novel acquisition instruments (multipolar catheters combined with improved physical

102 modelling and machine learning techniques) will enable enhanced and automated interpretation
103 of EGM recordings in the near future.

104 **Keywords:** atrial fibrillation, signal recording, signal processing, mapping, machine learning,
105 cardiac implantable electronic devices.

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129 **1. Introduction**

130 Recording, processing and subsequently interpretation of electrical activity of the atria is
131 essential for diagnosis and guiding (ablation) therapy of atrial fibrillation (AF). Atrial electrical
132 activity in clinical practice can be measured using body surface electrocardiograms (ECG) or
133 endo- and epicardial electrograms (EGM); optical action potentials are also used in research
134 settings. ECGs recorded by implantable loop recorders or EGMs by pacemaker and ICDs can
135 be used for AF detection.

136 In the electrophysiology laboratory, analysis of EGMs recorded by catheters plays an important
137 role in adjunctive ablation strategies performed in addition to pulmonary vein isolation,
138 particularly in patients with (longstanding) persistent AF. However, electrical activity during
139 AF is highly complex requiring advanced mapping systems equipped with sophisticated
140 processing technologies for identification of suitable target sites for ablation. As standard
141 approaches for recording and processing electrical activity during AF do not exist a lot of effort
142 has been put in clinically evaluating a variety of mapping systems yet with mixed outcomes.
143 Many of the currently available recording and processing technologies are also restricted to
144 specific applications or have technological limitations hampering wide-spread applicability.
145 Importantly, guidelines or recommendations in this area currently do not exist.

146

147 **Aims and Scope**

148 The objectives of this document are to 1) provide a critical appraisal of basic concepts
149 underlying signal recording and processing technologies applied for AF mapping to unravel
150 AF mechanisms and/or identifying target sites for AF therapy and AF detection, 2) discuss
151 clinical values and limitations based on unique features of these technologies, 3) advise on their

152 applications and 4) to identify unmet needs in context of signal recording and processing. This
153 position paper provides up-to-date knowledge for clinicians, engineers and researchers to
154 optimize usage of signal recording and processing methodologies, stimulate research aimed at
155 closing knowledge gaps and developing ideal AF recording and processing technologies. As
156 novel signal recording and processing technologies are continuously being developed, we do
157 not aim to review all features offered by currently existing mapping systems.

158

159 **2. Electrograms**

160 **2.1 Unipolar and bipolar EGMs**

161 An EGM is the extracellular potential difference between two adjacent electrodes (bipolar, Bi-
162 EGM) or the potential difference between one single electrode in tissue contact relative to an
163 indifferent electrode at zero potential or Wilson Central Terminal (unipolar, U-EGM). Figure
164 1 shows examples of U-EGM and corresponding Bi-EGM recorded during AF.^{1, 2} Although
165 AF mapping is most frequently performed with Bi-EGM, U-EGM are nowadays also
166 increasingly being used. So far, differences between U-EGM and Bi-EGM for AF mapping
167 have only been examined for identification of low voltage areas in single centre clinical studies
168 and experimental studies (section 4.2) and of endo-epicardial asynchronously activated areas
169 in experimental studies (section 6.2). The advantage of U-EGMs is that determination of local
170 activation time (LAT) is straightforward (section 4.1). The main disadvantage of U-EGMs is
171 that local fibrillation potentials may be masked by far-field potentials or distant atrial activity
172 caused by the ventricles and multiple fibrillation waves, as U-EGMs are sensitive to remote
173 electrical activity. So far, in only one report, U-EGM features ($dV/dT_{max} < 0.05V/s$, amplitudes
174 $< 0.2mV$ and durations $> 35ms$) used to discriminate local from far field fibrillation potentials
175 have been described.³ The major advantage of Bi-EGM is its relative insensitivity to remote
176 electrical activity and electrical noise (due to common mode rejection) and it is therefore often

177 the preferred recording mode used for AF mapping^{1,2}. However, a disadvantage of Bi-EGM is
178 that its amplitude depends on wavefront direction; when a fibrillation wave passes both
179 electrodes at the same time, subtraction of virtually equal U-EGMs results in no residual Bi-
180 EGM. Annotation of LAT is also more ambiguous (section 4.1). In addition, Bi-EGM
181 morphology not only depends on interelectrode spacings,⁴ but also on conduction velocity (CV)
182 and direction of the fibrillation waves which both vary from beat-to-beat during AF.
183 Thus, Bi- and U-EGM have their own (dis) advantages (Table 1) for AF mapping and their
184 morphology is affected by various variables (supplemental Table 1). At present, there are no
185 clinical studies demonstrating that either U- or Bi-EGM are more suitable for AF mapping. As
186 they provide complimentary information, combined usage for AF mapping could be beneficial.

187

188 **2.2 Multipolar EGMSs**

189 Multipolar EGM include Laplacian and omnipolar EGMs (Figure 2). Laplacian EGMs are
190 calculated by subtracting the centre electrode U-EGM from the U-EGM of either evenly
191 distributed surrounding close-by electrodes, (fixed electrode-array), or sequentially obtained
192 EGMs weighted for distance utilizing an electro-anatomical mapping system.⁵ If electrodes
193 are close together, Laplacian EGMs approximate the second-order spatial derivative of the U-
194 EGM. Omnipolar EGMs yield EGMs independent from the orientation of the recording
195 electrodes, and hence wavefront direction. They are calculated within a clique, which is defined
196 as a square of 4 electrodes from which the Bi-EGM with the largest amplitude is extracted.

197 Experiences with multipolar EGMs such as Laplacian and omnidirectional EGMs during AF
198 are limited to voltage mapping in experimental settings in canine and human atria.^{5,6} Table 1
199 summarizes (dis)advantages of omnipolar and Laplacian EGMs. So far, there are no clinical
200 studies demonstrating advantages of multipolar EGM over U- and Bi-EGM for AF mapping.

201

202

203

204 **2.3 Impact of recording technology on EGM morphology**

205 EGM morphology is affected by the size of recording electrodes, shapes of electrodes (printed
206 on splines or integrated in catheter shaft), inter-electrode distances, filtering and the sampling
207 rate of digitization (supplemental Table 1). Smaller diameter electrodes result in higher
208 frequency and amplitude potentials of both U- and Bi-EGM ⁷ but also higher noise levels
209 caused by higher input impedances. ^{8,9} A decrease in interelectrode distances is associated with
210 a decrease in voltages and fractionation. ^{10, 11} Filtering and the sampling frequency also
211 influence EGM characteristics. ¹² According to the Nyquist principle, the sampling rate should
212 be at least twice the highest intended frequency content to be measured. Filtering may attenuate
213 respiration or movement artifacts, interference and far-field components, but it also affects
214 EGM morphology. ^{1, 2, 9} Especially high-order filters that attenuate certain frequencies more
215 steeply, may disturb EGM morphology significantly. ^{9, 12} Such filters are prone to ringing and
216 may generate artificial deflections. Low- and high pass filtering may respectively increase and
217 decrease amplitudes of U-EGM; both low- and high pass filtering decreases fractionation of
218 U-EGM recorded during AF. ^{1, 9} Notch filtering increases fractionation of U-EGM during AF
219 and reduces amplitudes. ⁹ Hence, filtering significantly affects the already complex morphology
220 of EGM recorded during AF and should therefore be avoided as much as possible.

221

222 **Invasive mapping of atrial fibrillation**

223 **3.1 Local versus global mapping modes**

224 Cardiac mapping is defined as a methodology by which electrical potentials recorded from the
225 heart are spatially depicted in an integrated manner, usually as a function of time. ¹³
226 Identification of underlying mechanism(s) and arrhythmogenic substrates by mapping of AF is

227 slowly progressing. In contrast to mapping uniform arrhythmias with a stable and defined focal
228 or re-entrant mechanism, AF mapping is challenging, as AF is neither purely focal nor stable
229 re-entry in nature.^{14, 15} Thus, conventional mapping catheters and algorithms assuming
230 spatiotemporal EGM stability are not applicable to AF mapping. There is no consensus on how
231 long AF episodes should be recorded to obtain a representative value of a specific parameter
232 and how to determine the electropathological variable which most accurately represents
233 arrhythmogenic tissue (e.g. mean, median, or ranges). Two concepts for recording of electrical
234 activity during AF are ‘global’ and ‘local mapping’.

235

236 **3.2 Global AF mapping**

237 Global mapping (‘panoramic view’) refers to simultaneous recording of EGMs of the entire
238 atria using large intracardiac basket catheter(s) (supplemental Figure 1) or body surface
239 electrodes (section 5). Endocardial, multielectrode basket catheters record up to 128 U-EGMs
240 simultaneously from multiple locations and can be used for e.g. activation or phase mapping.
241 Bi-atrial activity is recorded during a single interval which avoids interpolation associated with
242 combining sequential data from multiple intervals.

243 Non-randomised clinical studies demonstrated that ablation targeted at stable rotational activity
244 and focal sources could eliminate AF.^{16, 17} Algorithms using data recorded by these basket
245 catheters are often biased toward detection of rotational activities even when these do not exist;
246 focal activation might be displayed as rotational activity if the wavefront reaches surrounding
247 electrodes sequentially.^{18, 19} Advantages of these catheters are that they measure contact EGMs
248 and allow real-time evaluation of propagation for guiding ablation. However, they also have
249 significant limitations: 1) suboptimal electrode-tissue contact at many poles; 2) splines are not
250 equidistantly separated, 3) low spatial resolution, 4) lack of reproducible positioning, 5)
251 recordings contain spline touch artefact’s, 6) higher pro-coagulative tendency, 7) septum and

252 coronary sinus are not included. Additionally, the amount of extrapolation used for
253 construction of e.g. activation time maps is difficult to determine. Although initial, non-
254 randomised studies in patients with AF were promising, a randomised, controlled, multicentre
255 clinical trial failed to demonstrated successful outcomes of ablative therapy guided by global
256 mapping.²⁰

257

258 **3.3. Local AF mapping**

259 Local mapping refers to high density mapping of smaller regions using contact multipolar
260 catheters; the catheter moves consecutively through the atria to obtain local electrical activity.
261 During local mapping, contact catheters directly record, rather than estimate, EGMs. This can
262 be achieved epicardially with high-density electrode grids placed during surgery²¹ or
263 endocardially with multielectrode mapping catheters introduced percutaneously (supplemental
264 Figure 1).²² The resulting maps have a high local resolution but however, limited global
265 resolution. Maps created with roving catheters often utilize Bi-EGM rather than U-EGM. A
266 benefit of multielectrode mapping catheters over linear ablation catheters is the higher
267 likelihood that electrodes are in contact with tissue, reducing the effect of catheter angle on
268 EGM morphology.²³⁻²⁵ Also, multi-electrode grids allow fixed uniform and reproducible
269 interpolation unlike spline or basket multi-electrode catheters.

270 Multielectrode mapping catheters with smaller electrodes and closer interelectrode spacing
271 increase the mapping resolution.^{22, 26} However, the optimal mapping resolution during AF is
272 yet to be defined. Also, the larger number of data points recorded by multielectrode mapping
273 catheters precludes real-time manual annotation of individual signals, thus, creating
274 dependency on automated algorithms and their accuracy. Simultaneous construction of
275 endocardial and epicardial contact maps accounting for transmural activation sequences may
276 be warranted in AF but has not yet been clinically implemented.³

277
278
279
280

4. Signal processing technologies

281 Signal processing refers to analysis, usually automated, of EGMs. Analysis is focused on
282 identifying specific parameters defining individual EGM characteristics with the principal aim
283 of rapidly interrogating the arrhythmogenic substrate and targeting sites critical to AF
284 maintenance. Various signal processing techniques applicable for AF mapping discussed
285 below are summarized in Table 2.

286

4.1 Local activation time mapping

288 A LAT map depicts the activation time at every recording site relative to a reference point.²⁷
289 ²⁸ LAT mapping is used to visualize patterns of activation to e.g. discriminate between re-entry
290 and focal activity or to identify slow, crucial zones of slow conduction by superimposing
291 isochrones. Figure 3 illustrates examples of difficulties encountered in annotation LAT of U-
292 and Bi-EGM. LAT maps using U-EGM are based on the principle that the timing of $-dV/dT_{max}$
293 coincides with the time of maximum rate of rise of the transmembrane potential (time
294 differences less than $50 \mu s$ ²⁹) corresponding to the maximum increase in sodium current and
295 its conductance. LAT determination using Bi-EGM is more complex; bipolar LAT maps are
296 constructed by annotating the onset, peak or $-dV/dT_{max}$ of Bi-EGM. An accurate algorithm for
297 LAT annotation utilizes the $-dV/dT_{max}$ of the first-order spatial derivative of the underlying U-
298 EGM. This assumes that shape and velocity of the propagating wavefront remains constant,
299 which is usually not the case during AF. Activation time mapping is an effective approach if
300 EGMs consist of a single negative deflection but is challenging if EGMs are fractionated or
301 contain continuous electrical activities. Several advanced signal processing technologies have
302 been proposed to improve automated analysis of complex EGMs, including investigation of

303 signal morphology, wavelet decomposition, deconvolution and wavefront tracking, yet clinical
304 benefits of these technologies have not yet been demonstrated.^{28, 30-33}

305 **4.2. Voltage mapping**

306 A voltage (V) map depicts the peak-to-peak amplitudes of EGMs at multiple sites
307 (supplemental Figure 1). However, both unipolar (UV) and bi-polar voltage (Bi-V) are
308 influenced by numerous variables (supplemental Table 1). UVs are larger than Bi-V; only when
309 the maximum V at one electrode nearly coincides with the minimum V at the other electrode,
310 then the V of the negative deflection of Bi-EGM equals the peak-to-peak V of U-EGM (left
311 panel Figure 1). Another determinant of EGM-V is rate and hence cardiac rhythm.³⁴ There is
312 a modest correlation between Bi-V measured during AF and sinus rhythm, which becomes
313 weaker in patients with more persistent types of AF.³⁵ Bi-V are higher during sinus rhythm
314 compared to AF. During atrial extra stimuli with decreasing coupling intervals, Bi-V were more
315 attenuated than UV.³⁴ Despite numerous variables affecting EGM-V, low endocardial Bi-V are
316 regarded as surrogate markers of fibrotic tissue and low voltage areas have therefore become
317 targets for ablative therapy in patients with AF³⁶. It is important, however, to emphasize that
318 there is limited data correlating low voltage areas to mechanisms initiating or perpetuating AF.
319 ³⁶ Several definitions of voltage thresholds related to ‘scar tissue’ have been introduced e.g. 0.5
320 mV (most often used, 5th percentile obtained during supraventricular tachycardia), 0.05mV
321 (noise level electro-anatomical mapping system), 0.2 mV for the posterior left atrial wall (5th
322 percentile of V histograms of patients with paroxysmal AF) or <0.1mV (‘dense scar’, patients
323 with persistent AF).³⁷⁻³⁹ However, none of these thresholds have been validated pathologically
324 and outcomes of ablation targeting bipolar low voltage areas -either during sinus rhythm or
325 AF- show conflicting results.⁴⁰ Possible explanations for these discrepancies include mapping

326 and/or ablation strategies and patient selection. Also, since voltage depends on size and
327 distances of electrodes, voltage maps acquired with different catheters should not be compared.

328

329 **4.3. Complex fractionated atrial electrograms mapping**

330 Complex fractionated atrial electrograms (CFAE) maps depict the location of CFAEs
331 (supplemental Figure 1). CFAE are most often defined as potentials with 3 or more negative
332 deflections. However, in literature, at least 27 different definitions and/or methodologies for
333 identification of CFAE have been introduced (Table 3).⁴¹ A review of 84 studies targeting
334 CFAE, reported on absence of CFAE predilection sites in the right or left atrium and also no
335 differences in degree of fractionation between patients with paroxysmal or persistent AF.^{41, 42}
336 These findings are, however, not surprising, giving the variable methodologies applied. Also,
337 how fractionated Bi-EGM should be correctly annotated is unknown. The mechanistic role of
338 CFAEs in AF stems from the earlier work by Konings et al. who performed unipolar epicardial
339 mapping of induced AF in patients with Wolff-Parkinson-White syndrome undergoing cardiac
340 surgery.⁴³ By comparing U-EGM morphology and underlying activation patterns, they
341 demonstrated that CFAEs during AF correlated to sites of pivot points and slow conduction.
342 This led to the conclusion that CFAE areas during AF represent either continuous re-entry of
343 fibrillation waves into the same area or overlap of different wavelets entering the same area at
344 different times. This observation supports the hypothesis that AF is driven and maintained by
345 multiple wavelets. Kalifa et al. proposed that fractionation occurs due to interruption of an
346 activation wavefront as it crosses from one tissue boundary into another.⁴⁴ This hypothesis
347 supported the observation that fractionation was highest at boundaries of dominant frequency
348 (DF) domains (i.e. sites of highest DF and lowest frequencies) caused by differences in
349 electrophysiological properties (refractory periods, CV etc.) of adjacent myocardial tissue.

350 These findings not only dispute the multiple wavelet hypotheses but also propose that 1) AF is
351 driven and maintained by rotors and CFAE are located adjacent to sources, 2) these sources
352 correlate to sites of highest DF and highest regularity index (RI) i.e. sites of fastest and most
353 organized activity and 3) that creation of borders at CFAE sites results in AF termination.
354 However, others argued that there is only a modest spatial correlation between CFAE sites and
355 highest DF and with the different responses to ablation at these sites respectively this may
356 indicate that CFAE and DF domains are separate entities.⁴⁵ A multicentre, randomized trial
357 indeed demonstrated that CFAE ablation did not reduce AF recurrences on the long-term.^{46, 47}

358 **4.4 Dipole density mapping**

359 Dipole density mapping refers to utilization of dipole density -defined as ‘cellular charge
360 sources’- to resolve local electrical activation.^{48, 49} Data from an ultrasound array is used for
361 reconstruction of the anatomy⁴⁹. Non-contact electrodes sense intracavitary U-EGMs from
362 which dipole densities are derived based on the precise ultrasound measured distance and
363 reconstructed endocardial surface area. From these dipole densities, forward-calculated EGMs
364 are reconstructed. A prediction model instead of data interpolation is used between the
365 measuring points. Fundamental differences between voltage and dipole density lie in the
366 averaging effect of “spatial summation” and in the volume of space occupied by each.
367 Theoretically, dipole density–based mapping provides a more localized portrayal of activation
368 patterns than voltage-based mapping does, and with less far-field interference.

369 The accuracy of non-contact dipole density map was compared to contact voltage mapping
370 during sinus rhythm and AF and correlated well when the recorded sites were ≤ 40 mm from
371 the endocardial surface, comparable to previously published for non-contact mapping
372 systems.⁵⁰ The theoretical benefits of dipole density mapping and initial clinical outcomes from
373 single center studies require further validation in randomized controlled trials.^{50, 51}

374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397

4.5 Rotational activity mapping

Rotational activity is caused by functional reentry circuits (supplemental movie 1) with an excitable but non-excited core and a curved wavefront subject to source-sink mismatch driving spiral waves.⁵²Phase analysis is used to identify rotors based on identification of the phase singularity point and thereby the core of rotational activity driving AF. In phase mapping, the converted EGM is mathematically transformed to capture wavefront dynamics through the activation-recovery cycle of the underlying tissue, effectively functioning as a low-pass filter implemented on fractionated EGMs.⁵³Phase analysis is particularly suited to optical mapping of action potentials with their characteristic depolarisation upstroke, intervening plateau and repolarisation downslope and has been used effectively for AF analysis in experimental models.⁵⁴ However, as the type of signals recorded, and the technique employed influences phase analysis it remains unclear whether rotational activity seen during mapping of AF in humans are representative of the same re-entry mechanism demonstrated with optical mapping⁵⁵. In computational and experimental models, rotational activities maintain AF and therefore have been considered ablation targets. Limitations of mapping in humans that may influence the phase analysis and thereby interpretation of phase maps includes: (1) artefact due to noise, (2) far field ventricular signals and (3) limited resolution with mapping catheters particularly basket catheters resulting in data interpolation. Interpolation of phases may result in representation of non-existent rotors as the interpolation algorithm is devised to detect rotational activity.^{18, 19, 56} Therefore, it remains unclear whether the current mapping modalities

398 available in humans are able to effectively identify source mechanisms that have so elegantly
399 been demonstrated in animal models with optical mapping. Furthermore, characteristics of
400 these localised sources remain unclear. Spatiotemporal stability of rotational activities has been
401 demonstrated in optical mapping studies in animal models, however, mapping of rotational
402 activity in humans has shown inconsistent results.^{16, 17, 57, 58} Whilst some studies conclude that
403 these drivers are spatiotemporally stable¹⁶ others have shown that even though spatially stable
404 the drivers elicit temporal periodicity.⁵⁷ It remains unclear which of these characteristics are
405 the correct description of these drivers and if both are, does the temporal stability have an
406 impact on the mechanistic importance of these drivers? These questions remain to be answered.

407 **4.6 Atrial rate analysis**

408 The activation rate of a recording site can be estimated in the time domain in terms of average
409 cycle length, while several indices related to activation organization can be obtained from the
410 dispersion of the cycle length histogram. However, this approach requires the use of automatic
411 algorithms to estimate LATs or cycle lengths, which can be challenging in case of CFAE.⁵⁹
412 Atrial rate can also be computed in the frequency domain, avoiding the need of LAT detection.
413 In order to ensure that the maximum spectral amplitude corresponds to the atrial rate and not
414 to one of its harmonics, Botteron's preprocessing^{60, 61} is applied to the raw signal before
415 computing the spectrum. This preprocessing (supplemental Figure 2) consists of three steps:
416 band-pass filtering, rectification and low pass filter removing details of the individual
417 activations and converting the raw signal in a train of smooth pulses. The dominant frequency
418 is defined as the highest spectral peak of this preprocessed signal. The organization index has
419 been defined as the ratio of the spectral power around the dominant frequency and its harmonics
420 to the total spectral power.⁶² This index measures the periodicity of the preprocessed signal,
421 which is a sign of periodic and organized activations. Spatial distribution of activation rate and

422 activation organization have been studied to find AF critical sources, and therefore, candidate
423 sites for ablation, based on the hypothesis that high activation rates and organization allows
424 identification of sources driving AF.⁶³ While reduction of dominant frequency has been shown
425 to be a marker of good ablation outcome,⁶⁴ direct ablation of sites with maximum dominant
426 frequency have shown mixed results.⁶⁵⁻⁶⁷

427 **4.7 Conduction velocity and activation direction analysis**

428 Conduction velocity (CV) along a given activation direction (AD) can be measured from
429 differences of LATs at electrodes with known 2-dimensional interelectrode distances (Figure
430 4).^{28, 68, 69} However, CV can only be estimated as the true 3-dimensional pathway is unknown.
431 CV can be semi quantitatively visualised by construction of isochronal maps. Model-based
432 approaches have been used to estimate both CV and AD, using LAT from EGMs recorded by
433 circular catheters or multielectrode arrays⁶⁸. In general, CV and AD maps can be obtained by
434 postprocessing activation maps if they have enough spatial resolution,⁷⁰ but they may be very
435 sensitive to errors and inconsistencies in LAT estimates. To cope with this problem, Anter et
436 al⁶⁹. proposed a method which estimates a consistent global pattern of activation in the whole
437 chamber, taking into account all candidate LATs in a single electrogram, and then locally
438 estimated CV and AD. Uncertainties in LAT estimation have been quantified and used for LAT
439 interpolation.⁷¹ Recently, van Schie et al. introduced a novel, modified discrete velocity vectors
440 methodology to calculate CV.⁷² CV during AF is calculated to identify areas with low CV
441 associated with structural remodeling. However, as the true pathlength is unknown, particularly
442 in complex patterns of activations during AF, the calculated ‘effective’ CV may only be
443 roughly estimated.

444 **4.8 Entropy**

445 Entropy is a dimensionless parameter of randomness, used in information theory to measure
446 information content, estimate signal variability or randomness in time series data and can
447 therefore be used to evaluate EGM complexity objectively.⁷³ When applied to EGMs, low
448 values indicate high regularity and predictability whereas high values increase progressively
449 with irregularity and are highest for random noise. The amplitude histogram based Shannon
450 entropy measure was only moderately inversely correlated with CFAE⁷³. A recent single center
451 study demonstrated that sample entropy, which uses EGM segment vector comparisons, is
452 correlated with outcomes of ablation therapy in persistent AF patients undergoing CFAE
453 ablation.

454 **5. Non-invasive mapping of AF**

455 ECG Imaging (ECGI) is a non-invasive, body surface mapping technique (Figure 5) for
456 reconstruction of cardiac excitation patterns using 80-250 electrodes applied to the upper
457 torso.⁷⁴⁻⁷⁶ Prior to this, the cardiac anatomy and electrode positions are determined either via
458 medical imaging (CT or MRI scans) or with 3D localization technology.^{74, 77} Numerical
459 inversion provides real-time estimates of epi- and endocardial U-EGMs, excitation wavefronts,
460 or transmembrane voltages. From these, atrial maps of various quantities (e.g., activation time,
461 voltage, phase, conduction velocity, and dominant frequency) can be derived and specific
462 phenomena can be localized (e.g., ectopic foci, phase singularities, and rotors/rotor densities).
463 Because of severe numerical problems, only a few investigators attempted to estimate
464 transmural potentials. Inversion requires an accurate forward model including a source and an
465 observation model. The observation model is a volume conductor model of the torso relating
466 cardiac sources to body surface potentials. Relatively large distances between sources and
467 electrodes translate into spatial blurring which the inversion tries to correct, but this is
468 complicated as there are far fewer electrodes than source locations. The source model describes
469 generation and spatiotemporal propagation of excitation, and depends on many hidden

470 parameters—this serves as a prior to the solution. In practice, this is replaced by patient-
471 independent assumptions and constraints on spatiotemporal smoothness. Priors are needed for
472 regularization, because inversion is inherently an ill-posed problem with ambiguous solutions.
473 Current systems reach resolutions of 10-20 mm, with wide standard deviations.⁷⁸ Temporal
474 fidelity is often limited; estimated activation times have errors of 10-20ms. Also, artefacts like
475 spurious lines of block are reported.⁷⁹ Due to their lower amplitude, atrial signals are harder
476 to reconstruct than ventricular signals.

477 The promise of ECGI is that it will provide clinicians with non-invasive panoramic maps before
478 the patient moves into the EP-lab, allowing anatomic characterization and localization of AF
479 drivers, and therefore targets for ablation prior to procedures.⁵⁷ ECGI could also help verify
480 permanent post-ablation conduction block or identify gaps in ablation lines before re-do
481 procedures.⁸⁰ As a research tool, ECGI provides a means of studying AF and poorly-
482 understood mechanisms like reentry circuits, rotors and rotor densities, areas of slow
483 conduction, focal sources, CFAEs and dominant frequency heterogeneities.⁸¹ Combined with
484 LGE-MRI, it can identify locations where rotors anchor to fibrotic substrates—potential
485 ablation targets.⁸²

486 However, validation of ECGI remains a significant challenge. Comparison of ECGI to EGMs
487 using an intracardiac catheter mapping showed general agreement with several important
488 limitations,^{53, 83, 84} primarily related to numerical challenges in the inversion. The technique is
489 sensitive to ECG noise and motion (cardiac cycle, breathing), sometimes resulting in artefacts
490 or outliers. Regularization techniques make generic assumptions on source parameters and it
491 is unclear how that impacts accuracy. Detection of small amplitude EGMs or drivers with short
492 cycle lengths using ECGI may not be reliable, in particular the assessment of drivers in the
493 septal area is challenging. Moreover, the clinical workflow is complex, requiring application
494 of an electrode vest, its anatomical registration and subsequent image processing that has not

495 yet been fully automated and may be hampered by patient-specific factors. This has limited its
496 clinical adoption. Hence, translation of ECGI maps into reliable disease markers requires
497 additional studies.⁸⁵

498

499

500 **6. Research tools for AF mapping**

501 **6.1 Optical mapping of AF**

502 Optical mapping involves use of voltage-sensitive dyes to examine spatiotemporal excitation
503 patterns in cardiac tissue (Figure 6).⁸⁶ This technique has been used in animal models to
504 elucidate tissue-scale or organ-scale atrial electrophysiology, including characterization of
505 anti-arrhythmic drug effects, understanding cellular and molecular AF mechanisms, and
506 exploring the prospect of light-based optogenetic cardioversion⁸⁶⁻⁸⁸. In contrast to isolated cell
507 models, optical mapping enables analysis of non-disrupted myocardium in its native
508 electrophysiological milieu. Recent advances have evaluated interplays between 3-dimensional
509 tissue fibrosis and AF mechanisms.⁸⁹ These data have been used to calibrate computational
510 models that realistically reproduced reentrant arrhythmia drivers seen in-vitro. Insights
511 obtained from such studies may be useful to improve calibration of image-based computational
512 models in contemporary studies.^{90,91} Disadvantages of optical mapping include applicability
513 to only ex vivo cardiac tissue construction of solely 2-dimensional images. As a research tool,
514 modern mapping technologies may integrate essential findings from optical mapping data
515 specifically on large-scale tissue activation. Progress in this area will likely be hastened by the
516 recent publication of open experimental protocols for relatively inexpensive construction of
517 panoramic optical mapping systems.^{92,93} Notably, interpretation of data from optical mapping
518 could account for limitations of experimental systems, such as the absence of extracardiac
519 sympathetic or parasympathetic regulation of Langendorff-perfused hearts. Moreover, recent

520 findings show that usage of Blebbistatin to reduce motion artifacts in optically mapped hearts
521 via blocking excitation-contraction leads to non-physiological action potential duration
522 prolongation.⁹⁴

523

524

525 **6.2 Epicardial mapping of AF**

526 Cardiac surgery offers the opportunity to perform mapping (Figure 4) of the atrial epicardium.
527 Epicardial mapping can be performed with arrays containing a high number of electrodes
528 (>100) with small diameters (0.4-0.6mm) and interelectrode distances (2-2.5 mm).^{21, 95} As
529 these arrays are manually positioned on the epicardium, stable contact between electrodes and
530 atrial tissue is ensured. Also, exact locations of the electrode array in relation to anatomical
531 structures is visualized. Another advantage of this mapping approach is access to regions which
532 cannot be reached from the endocardium such as Bachmann's Bundle.⁹⁶ Electrode arrays used
533 during cardiac surgery records EGM at multiple sites simultaneously, which is essential for
534 understanding AF mechanisms. Simultaneous mapping of the endo-epicardium during surgery
535 has indeed unravelled endo-epicardial electrical asynchrony as potential novel mechanism
536 underlying AF persistence.³ A disadvantage is the sequential mapping approach and the
537 electrode arrays are custom-made and therefore not clinical available. At present, there are no
538 clinical studies demonstrating the value of epicardial mapping guiding (surgical) ablation
539 procedures.

540

541 **7. Detection of atrial fibrillation**

542 **7.1 ICD/Pacemakers**

543 In recent years, an increasing number of cardiac implantable electronic devices (CIEDs) have
544 been implanted in patients with cardiovascular diseases. CIEDs enable AF detection with

545 storage of intracardiac EGM for evaluation at any time. As a result of continuous monitoring
546 of a growing number of patients, AF detection has increased dramatically, potentially
547 impacting therapeutic strategies.⁹⁷ Atrial high rate EGM (AHREs) are commonly used to
548 detect AF. AF detection algorithms vary between different CIEDs. Generally, in all CIEDs,
549 the PP intervals are continuously monitored. Different models of associating the detected PP
550 intervals to the programmed PP values are used to identify AF (Table 4). Moreover, it should
551 be noted that AF detection by CIEDs is not always correct, particularly when repetitive non-
552 reentrant ventriculo-atrial synchrony ensues.⁹⁸

553

554 **7.2 Implantable loop recorders**

555 Implantable loop recorders (ILRs) with dedicated AF algorithms are used for diagnosis and
556 monitoring of AF after surgical or catheter AF ablation, and cryptogenic stroke⁹⁹⁻¹⁰⁴. ILRs have
557 high accuracy in detecting AF burdens using incoherence of R-R intervals over a period of
558 time.¹⁰⁵⁻¹⁰⁸ Lorenz plots have extensively been used to demonstrate RR interval irregularity
559 during AF and to discriminate between AF and sinus rhythm. Different ILR models equipped
560 with algorithms for AF detection can accurately quantify AF burden (98.5 %) and are very
561 sensitive (96.4 %) to identify asymptomatic patients with AF^{106, 107}. In order to reduce the rate
562 of false positive AF episodes, an ILR with a long sensing vector has been utilized.¹⁰⁹ Moreover,
563 ILR algorithms were improved to detect visible P waves in the absence of noisy baseline or
564 flutter waves and were enhanced with artificial intelligence tools that learn if a patient has P-
565 waves during periods of RR irregularity. Performance of AF detection algorithms in ILRs
566 depends significantly on the patient population, incidence rate of AF, duration of monitoring
567 and type of AF. For example, diagnostic sensitivity will get closer to 100% for longer
568 monitoring duration or in patients with persistent AF^{108, 110, 111}. Therefore, prolonged

569 monitoring periods (> 3 years) are a prerequisite for the improvement of the ILR's diagnostic
570 yield.

571

572 **8. Post-processing of electrical signals**

573 Advances in the field of Artificial Intelligence (AI) and in particular Machine Learning (ML),
574 offer new opportunities to improve analysis of electrical signals.^{112, 113} Rapid progression in
575 computational power, data storage and remote data acquisition have enabled the application of
576 ML to ECGs and EGMs.¹¹² Table 5 provides a non-exhaustive list of potential applications of
577 ML in AF^{113, 114}. For the discussion of the application of Artificial Intelligence (AI) for
578 detection of AF we refer to recent scientific documents.^{115, 116}

579 ML has several limitations and challenges. First, external validity and generalizability remain
580 to be determined. The real value of this new approach in addition to clinical risk factors and
581 risk scores requires further investigation and validation. Second, while large amounts of data
582 can increase effectiveness of ML models, it is more difficult to critically assess their quality.
583 Third, black box ML methodologies inhibit interpretation and makes it impossible to involve
584 stakeholders in meaningful shared decisions. Fourth, as we move away from intuition and
585 physiologically-reasoned model-based approaches towards large (and deep) multivariate ML
586 models, we lose interpretability and potentially increase the likelihood of catastrophic outputs,
587 resulting in non-causal associations.

588

589 **9. Conclusion**

590 Recording and processing of EGMs are the cornerstones of mapping of AF. Yet, at present, it
591 is unknown what the most ideal EGM recording type (e.g. uni-, bi- or omnipolar) is and thus
592 which technology should be used for recording and processing. The combination of a lack of
593 golden standard of EGM recording and processing technology during AF and of a

594 comprehensive understanding of mechanism(s) underlying AF, does not give significant
595 confidence in comparative evaluation of current technologies. AI has opened an new era for
596 signal processing, yet the clinical value still has to be further explored. CIEDS are increasingly
597 used to detect AF episodes, yet diagnostic yields need further improvement.

598 Suggestions according to the EHRA consensus documents classifications are summarized in
599 Table 6.

600

601 **Future perspectives**

602 Improvements in AF mapping by obtaining highest fidelity source signals – including catheter-
603 electrode combinations, to signal processing including filtering, digitization and noise
604 elimination is of utmost importance. The cleanest source signal, with minimal and/or clearly
605 understood processing and a well-defined protocol facilitates evaluation and clinical
606 application. A critical evaluation of signal recording and processing techniques takes into
607 account all assumptions and mathematical transformations. Rigorous evaluation and validation
608 of novel technologies involves e.g. large animal arrhythmia models and organized
609 tachyarrhythmias before extending application to AF. Algorithms integrated in signal
610 processing software should be provided in manuals and provided as supplements in scientific
611 publications. Simultaneous multi-electrode activation time mapping, optimized for signal
612 quality, electrode size, density, spacing and coverage resolved to continuous high-fidelity
613 propagation sequences with extraction of the arrhythmogenic substrate by automated software
614 in near real-time enables minimally manipulated extraction of electrophysiological
615 mechanisms underlying AF.

616 The ideal mapping system for AF should be able to automatically 1) detect noise sources and
617 have an optimised noise removal thereby improving the signal-to-noise ratio. 2) remove farfield
618 QRS signal from the atrial EGM 3) annotate fibrillation potentials, 4) identify specific

619 electrogram features related to arrhythmia development or maintenance. The arrhythmogenic
620 substrate underlying AF can be detected by AI and there is an integration of multiparametric
621 generated maps and images (e.g. MRI) with algorithms identifying sites of driver activity or
622 specific substrate parameters related to AF and a validated support for identification of ablation
623 targets. Finally, there is a real-time EGM monitoring to detect variations in AF maintaining
624 mechanisms and display of multiparametric maps.

625 The AF diagnostic yield of pacemaker/ICDs may be improved by enhancement of existing
626 algorithms by use of RR interval irregularity detection algorithms. Furthermore, adequate atrial
627 lead selection and positioning and optimal programming of atrial sensitivity may eliminate the
628 effects of near-field P-wave or far-field R-wave oversensing by the atrial lead, runs of
629 premature atrial complexes, electrical interference, myopotentials, or repetitive nonreentrant
630 ventriculo-atrial synchrony on accurate AF detection.

631 For ILRs, further improvement in the AF detection algorithm should integrate rejection of
632 ventricular extrasystoles in order to enhance the accuracy of AF diagnosis in patients presenting
633 significant RR interval irregularities. Developments in multimodal ML could be used for
634 prediction and prognosis from multimodal data (e.g., ECG, EGM, LGE-MRI), improving
635 understanding of the AF substrate, differentiating between paroxysmal AF and persistent AF,
636 and predicting the outcome of ablation therapies. Recent developments in Generative
637 Adversarial Network provide the potential to develop personalized models. Also, initial
638 experiences with ML guiding substrate-based ablation therapy of AF have been published.¹¹⁷⁻

639 ¹²³

640

641

642

643

644

645


646

647

648

649

650 Legends



651

652 Figure 1.

653 Left panel: U-EGMs and corresponding Bi-EGM demonstrating the relation between the peak-


654 to-peak amplitudes. Right panel: U-EGMs and corresponding Bi-EGMs, demonstrating that U-

655 EGMs do not always result in "simple" non-fractionated Bi-EGMs. On the other hand,

656 fractionated U-EGM may give rise to non-fractionated Bi-EGM. However, an increase in

657 fractionation complexity of U-EGM is associated with an increase in complexity of Bi-EGM.

658 *By courtesy of Mathijs van Schie.*



659

660 **Figure 2.**

661 Panel A: cliques enclosed by four electrodes are used to record 3 U-EGM (filter: 5-400 Hz)

662 visualized in the top of panel C. U-EGMs of three adjacent electrodes (1,2 and 3) are used to

663 derive Bi-EGM by subtracting one U-EGM from the other U-EGM such that two pairs of Bi-

664 EGMs (1-2 and 2-3) are constructed along the horizontal (red) and vertical (green) directions.

665 Bi-EGMs are filtered (30-400 Hz) and visualized in the centre of panel C. Both Bi-EGMs are

666 used to describe a depolarization wavefront as an electrical field which is electrode orientation-

667 independent. Panel B illustrates the projections along the time-axis of the electrical field

668 derived from both Bi-EGMs. This enables to mathematically obtain Bi-EGMs in any direction

669 without physically rotating a sensing electrode. The E-field is subsequently scaled to analogous

670 2D voltage signals from which the maximal extent over the interval (T) is calculated and


671 corresponds to the peak-to-peak amplitude of a Bi-EGM obtained along a unit vector direction.

672 Panel C: resulting omnipolar EGM, Panel D: corresponding Laplacian EGM. *By courtesy of*

673 *Mathijs van Schie.*

Annotation Uncertainties


A. LAT Estimation




B. Fractionation



C. Endo-epicardial Asynchrony




D. Filter settings



674

675 **Figure 3.**



676 Challenges encountered with annotation of potentials recorded during AF. Panel A: red dots
677 indicate the different time samples. Annotation of the steepest deflection can be calculated by
678 e.g. averaging the steepest deflection of all time samples, selecting time samples with the
679 steepest deflection, or averaging between maximum and minimum values. This information is
680 usually not provided in manuals or in methodology sections of scientific reports Panel B: In
681 case of multiple deflection with comparable slopes and amplitudes, additional criteria have to
682 be developed to determine local activation times (LAT). Panel C: As a result of endo-epicardial
683 asynchrony, endocardial LATs may be different from epicardial LATs. Panel D: Determination
684 of LAT is affected by the filter settings which has a considerable impact on U-EGM
685 morphology.



686

687 **Figure 4.**

688 High resolution maps of the left atrial wall (N=192, interelectrode distance 2mm) constructed
 689 during AF obtained from a patient during cardiac surgery. These maps demonstrate from the
 690 left to the right: activation times combined with isochrones, local conduction directions,
 691 conduction directions and magnitude of conduction velocities, peak-to-peak voltages. *By*
 692 *courtesy of Mathijs van Schie.*



693

694 **Figure 5.**

695 Upper panel: simulation of excitation of the right and left atrium. Lower panel:

696 Body surface maps of the right and left atrium based on simulated - and measured activation
697 times constructed during sinus rhythm with an eighty-channel active electrode system
698 (ActiveTwo, BioSemi, Amsterdam, The Netherlands).

699
700


701 **Figure 6.**

702 Schematic illustration of the use of an open source imaging toolkit for panoramic optical
703 mapping, as described by Gloschat et al. A: Experimental optical mapping setup, including
704 Langendorff-perfused heart. B: Heart image with superimposed silhouette (yellow) derived via
705 an automated thresholding process. C: Data projection points for reconstruction of panoramic
706 maps of optically-mapped data. D: Examples of optically-mapped action potentials recorded
707 from the epicardial surface of a rat heart, including annotations for activation and 80%
708 repolarization times. E-F: Spatial reconstructions of activation time (E) and 80% action
709 potential duration (F) from representative rat panoramic optical data. Images reproduced from
710 Fig. 1 (panels A-C) and Fig. 7 (panels D-F) of Gloschat et al. under the terms of the Creative
711 Commons Attribution 4.0 International License. To view a copy of this license,
712 visit <http://creativecommons.org/licenses/by/4.0/>.⁹³

713

714

715 **Supplemental Data**




716

717 **Supplemental Figure 1.**

718 A) Composite image of a 64-electrode basket catheter in different positions within the anatomic
 719 shell of the left atrium. Note the large LA surface (yellow dashed line) without contact with
 720 the basket electrodes-splines as well as the prolapsing splines through the mitral valve, B)
 721 multi-electrode grid for the endocardial approach, C) high density, electrode mapping array for
 722 the epicardial approach, D) LAT map of the right atrium (RA) demonstrating a reentrant circuit
 723 around an area of scar tissue (grey area) E) RA voltage map, F) RA fractionation map; CFAE
 724 sites, indicated by the red markers are superimposed on a bipolar voltage map.

725



726

727 **Supplemental Figure 2.**

728 The upper plot demonstrates a 2-second bipolar EGM recorded during AF without any filtering.

729 Right panel: power spectra containing frequency distributions of corresponding signals

730 indicated by the arrows. For the Botteron's Approach, first a 40-250 Hz band-pass filter is

731 applied to the original signal to remove the spectral content below 40 Hz and 250 Hz in order

732 to remove any noise (as indicated in the power spectrum in the right panel). The dominant

733 frequency in this signal is 99 Hz. Step 2 is a nonlinear time-domain rectification process that

734 results in the absolute value of the filtered signal. The power spectrum of this rectified signal

735 demonstrates a fundamental frequency peak follow by harmonics with decreasing amplitude.

736 The third step preserves only the low frequencies by applying a low-pass filter set at 20 Hz. In
737 the time domain, the result is a smoothed pulse shape without high-frequency oscillations. In
738 the frequency domain, this step does not have a large effect for detection of the fundamental
739 frequency, which is 5 Hz in this example. *By courtesy of Mathijs van Schie.*

740

741 **Supplemental Movie 1.**

742 Video excerpt of activation mapping during AF with a 64 electrode basket catheter in the left
743 atrium and the left superior pulmonary vein ostium. The clip shows a clockwise rotational
744 activation (with a period of 180ms) cantered around the orange point on the roof of the LA near
745 the left superior pulmonary vein ostium; this pattern of activation recurred without a significant
746 change for 7 consecutive cycles.

747

748 **Tables**

749 **(see attachments)**

750

751

752 **Acknowledgements**

753 The authors thank the EHRA Scientific Document Committee: Dr. Nikolaos Dagres, Prof.
754 Thomas Deneke, Prof. Arthur Wilde, Prof. Frank R. Heinzel, Prof. Christian Meyer,
755 Prof. Lucas Boersma, Prof. Radoslaw Lenarczyk, Prof. Luigi di Biase, Dr. Elena Arbelo, Dr.
756 Avi Sabbag, Prof. Pierre Jais, Prof. Milos Taborsky, Asso. Prof. Markus Stühlinger.

757

758 **References**

759 [1] Venkatachalam KL, Herbrandson JE, Asirvatham SJ. Signals and signal processing for the
760 electrophysiologist: part II: signal processing and artifact. *Circ Arrhythm Electrophysiol* 2011;
761 **4**: 974-981.

762 [2] Venkatachalam KL, Herbrandson JE, Asirvatham SJ. Signals and signal processing for the
763 electrophysiologist: part I: electrogram acquisition. *Circ Arrhythm Electrophysiol* 2011; **4**:
764 965-973.

765 [3] de Groot N, van der Does L, Yaksh A, Lanthers E, Teuwen C, Knops P, et al. Direct Proof
766 of Endo-Epicardial Asynchrony of the Atrial Wall During Atrial Fibrillation in Humans. *Circ*
767 *Arrhythm Electrophysiol* 2016; **9**.

768 [4] Correa de Sa DD, Thompson N, Stinnett-Donnelly J, Znojkwicz P, Habel N, Muller JG,
769 et al. Electrogram fractionation: the relationship between spatiotemporal variation of tissue
770 excitation and electrode spatial resolution. *Circ Arrhythm Electrophysiol* 2011; **4**: 909-916.

771 [5] Coronel R, Wilms-Schopman FJ, de Groot JR, Janse MJ, van Capelle FJ, de Bakker JM.
772 Laplacian electrograms and the interpretation of complex ventricular activation patterns
773 during ventricular fibrillation. *J Cardiovasc Electrophysiol* 2000; **11**: 1119-1128.

774 [6] Haldar SK, Magtibay K, Porta-Sanchez A, Masse S, Mitsakakis N, Lai PFH, et al.
775 Resolving Bipolar Electrogram Voltages During Atrial Fibrillation Using Omnipolar Mapping.
776 *Circ Arrhythm Electrophysiol* 2017; **10**.

777 [7] Beheshti M, Magtibay K, Masse S, Porta-Sanchez A, Haldar S, Bhaskaran A, et al.
778 Determinants of atrial bipolar voltage: Inter electrode distance and wavefront angle. *Comput*
779 *Biol Med* 2018; **102**: 449-457.

780 [8] Rocha PR, Schlett P, Kintzel U, Mailander V, Vandamme LK, Zeck G, et al.
781 Electrochemical noise and impedance of Au electrode/electrolyte interfaces enabling
782 extracellular detection of glioma cell populations. *Sci Rep* 2016; **6**: 34843.

- 783 [9] Starreveld R, Knops P, Roos-Serote M, Kik C, Bogers A, Brundel B, et al. The Impact of
784 Filter Settings on Morphology of Unipolar Fibrillation Potentials. *J Cardiovasc Transl Res*
785 2020; **13**: 953-964.
- 786 [10] Stinnett-Donnelly JM, Thompson N, Habel N, Petrov-Kondratov V, Correa de Sa DD,
787 Bates JH, et al. Effects of electrode size and spacing on the resolution of intracardiac
788 electrograms. *Coron Artery Dis* 2012; **23**: 126-132.
- 789 [11] Takigawa M, Relan J, Martin R, Kim S, Kitamura T, Cheniti G, et al. Detailed Analysis
790 of the Relation Between Bipolar Electrode Spacing and Far- and Near-Field Electrograms.
791 *JACC Clin Electrophysiol* 2019; **5**: 66-77.
- 792 [12] Stevenson WG, Soejima K. Recording techniques for clinical electrophysiology. *J*
793 *Cardiovasc Electrophysiol* 2005; **16**: 1017-1022.
- 794 [13] Yaksh A, Kik C, Knops P, Roos-Hesselink JW, Bogers AJJC, Zijlstra F, et al. Atrial
795 fibrillation: to map or not to map? *Neth Heart J* 2014; **22**: 259-266.
- 796 [14] Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of
797 focal discharge. *Am Heart J* 1959; **58**: 59-70.
- 798 [15] Moe GK, Rheinboldt WC, Abildskov JA. A Computer Model of Atrial Fibrillation. *Am*
799 *Heart J* 1964; **67**: 200-220.
- 800 [16] Narayan SM, Baykaner T, Clopton P, Schricker A, Lalani GG, Krummen DE, et al.
801 Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared with
802 trigger ablation alone: extended follow-up of the CONFIRM trial (Conventional Ablation for
803 Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation). *J Am Coll Cardiol*
804 2014; **63**: 1761-1768.
- 805 [17] Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller JM. Treatment
806 of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation

807 for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. *J Am Coll*
808 *Cardiol* 2012; **60**: 628-636.

809 [18] Allessie M, de Groot N. Rebuttal from Maurits Allessie and Natasja de Groot. *J Physiol*
810 2014; **592**: 3173.

811 [19] Pathik B, Kalman JM, Walters T, Kuklik P, Zhao J, Madry A, et al. Absence of rotational
812 activity detected using 2-dimensional phase mapping in the corresponding 3-dimensional phase
813 maps in human persistent atrial fibrillation. *Heart Rhythm* 2018; **15**: 182-192.

814 [20] Buch E, Share M, Tung R, Benharash P, Sharma P, Koneru J, et al. Long-term clinical
815 outcomes of focal impulse and rotor modulation for treatment of atrial fibrillation: A
816 multicenter experience. *Heart Rhythm* 2016; **13**: 636-641.

817 [21] de Groot NM, Houben RP, Smeets JL, Boersma E, Schotten U, Schalij MJ, et al.
818 Electropathological substrate of longstanding persistent atrial fibrillation in patients with
819 structural heart disease: epicardial breakthrough. *Circulation* 2010; **122**: 1674-1682.

820 [22] Anter E, Tschabrunn CM, Contreras-Valdes FM, Li J, Josephson ME. Pulmonary vein
821 isolation using the Rhythmia mapping system: Verification of intracardiac signals using the
822 Orion mini-basket catheter. *Heart Rhythm* 2015; **12**: 1927-1934.

823 [23] Sroubek J, Rottmann M, Barkagan M, Leshem E, Shapira-Daniels A, Brem E, et al. A
824 novel octaray multielectrode catheter for high-resolution atrial mapping: Electrogram
825 characterization and utility for mapping ablation gaps. *J Cardiovasc Electrophysiol* 2019; **30**:
826 749-757.

827 [24] Huemer M, Qaiyumi D, Attanasio P, Parwani A, Pieske B, Blaschke F, et al. Does the
828 extent of left atrial arrhythmogenic substrate depend on the electroanatomical mapping
829 technique: impact of pulmonary vein mapping catheter vs. ablation catheter. *Europace* 2017;
830 **19**: 1293-1301.

831 [25] Takigawa M, Relan J, Martin R, Kim S, Kitamura T, Frontera A, et al. Effect of bipolar
832 electrode orientation on local electrogram properties. *Heart Rhythm* 2018; **15**: 1853-1861.

833 [26] Anter E, Tschabrunn CM, Josephson ME. High-resolution mapping of scar-related atrial
834 arrhythmias using smaller electrodes with closer interelectrode spacing. *Circ Arrhythm*
835 *Electrophysiol* 2015; **8**: 537-545.

836 [27] Ellis WS, Eisenberg SJ, Auslander DM, Dae MW, Zakhor A, Lesh MD. Deconvolution:
837 a novel signal processing approach for determining activation time from fractionated
838 electrograms and detecting infarcted tissue. *Circulation* 1996; **94**: 2633-2640.

839 [28] Cantwell CD, Roney CH, Ng FS, Siggers JH, Sherwin SJ, Peters NS. Techniques for
840 automated local activation time annotation and conduction velocity estimation in cardiac
841 mapping. *Comput Biol Med* 2015; **65**: 229-242.

842 [29] Spach MS, Dolber PC. Relating extracellular potentials and their derivatives to anisotropic
843 propagation at a microscopic level in human cardiac muscle. Evidence for electrical uncoupling
844 of side-to-side fiber connections with increasing age. *Circ Res* 1986; **58**: 356-371.

845 [30] Bollacker KD, Simpson EV, Hillsley RE, Blanchard SM, Gerstle RJ, Walcott GP, et al.
846 An automated technique for identification and analysis of activation fronts in a two-
847 dimensional electrogram array. *Comput Biomed Res* 1994; **27**: 229-244.

848 [31] Alcaine A, Soto-Iglesias D, Calvo M, Guiu E, Andreu D, Fernandez-Armenta J, et al. A
849 wavelet-based electrogram onset delineator for automatic ventricular activation mapping. *IEEE*
850 *Trans Biomed Eng* 2014; **61**: 2830-2839.

851 [32] Vidmar D, Alhousseini MI, Narayan SM, Rappel WJ. Characterizing Electrogram Signal
852 Fidelity and the Effects of Signal Contamination on Mapping Human Persistent Atrial
853 Fibrillation. *Front Physiol* 2018; **9**: 1232.

854 [33] Ye Z, van Schie MS, de Groot NMS. Signal Fingerprinting as a Novel Diagnostic Tool to
855 Identify Conduction Inhomogeneity. *Front Physiol* 2021; **12**: 652128.

856 [34] Williams SE, Linton N, O'Neill L, Harrison J, Whitaker J, Mukherjee R, et al. The effect
857 of activation rate on left atrial bipolar voltage in patients with paroxysmal atrial fibrillation. *J*
858 *Cardiovasc Electrophysiol* 2017; **28**: 1028-1036.

859 [35] Ndrepepa G, Schneider MA, Karch MR, Weber S, Schreieck J, Zrenner B, et al. Impact
860 of atrial fibrillation on the voltage of bipolar signals acquired from the left and right atria.
861 *Pacing Clin Electrophysiol* 2003; **26**: 862-869.

862 [36] Anter E, Josephson ME. Bipolar voltage amplitude: What does it really mean? *Heart*
863 *Rhythm* 2016; **13**: 326-327.

864 [37] Sim I, Bishop M, O'Neill M, Williams SE. Left atrial voltage mapping: defining and
865 targeting the atrial fibrillation substrate. *J Interv Card Electrophysiol* 2019; **56**: 213-227.

866 [38] Masuda M, Fujita M, Iida O, Okamoto S, Ishihara T, Nanto K, et al. Left atrial low-voltage
867 areas predict atrial fibrillation recurrence after catheter ablation in patients with paroxysmal
868 atrial fibrillation. *Int J Cardiol* 2018; **257**: 97-101.

869 [39] Rodriguez-Manero M, Valderrabano M, Baluja A, Kreidieh O, Martinez-Sande JL,
870 Garcia-Seara J, et al. Validating Left Atrial Low Voltage Areas During Atrial Fibrillation and
871 Atrial Flutter Using Multielectrode Automated Electroanatomic Mapping. *JACC Clin*
872 *Electrophysiol* 2018; **4**: 1541-1552.

873 [40] Spragg DD, Zghaib T. Veracity of Voltage Mapping During Atrial Fibrillation and Flutter:
874 How Good Is Good Enough? *JACC Clin Electrophysiol* 2018; **4**: 1553-1555.

875 [41] van der Does LJ, de Groot NM. Inhomogeneity and complexity in defining fractionated
876 electrograms. *Heart Rhythm* 2017; **14**: 616-624.

877 [42] Starreveld R, van der Does L, de Groot NMS. Anatomical hotspots of fractionated
878 electrograms in the left and right atrium: do they exist? *Europace* 2019; **21**: 60-72.

879 [43] Konings KT, Kirchhof CJ, Smeets JR, Wellens HJ, Penn OC, Allessie MA. High-density
880 mapping of electrically induced atrial fibrillation in humans. *Circulation* 1994; **89**: 1665-1680.

881 [44] Kalifa J, Tanaka K, Zaitsev AV, Warren M, Vaidyanathan R, Auerbach D, et al.
882 Mechanisms of wave fractionation at boundaries of high-frequency excitation in the posterior
883 left atrium of the isolated sheep heart during atrial fibrillation. *Circulation* 2006; **113**: 626-633.

884 [45] Kumagai K, Sakamoto T, Nakamura K, Nishiuchi S, Hayano M, Hayashi T, et al.
885 Combined dominant frequency and complex fractionated atrial electrogram ablation after
886 circumferential pulmonary vein isolation of atrial fibrillation. *J Cardiovasc Electrophysiol*
887 2013; **24**: 975-983.

888 [46] Vogler J, Willems S, Sultan A, Schreiber D, Luker J, Servatius H, et al. Pulmonary Vein
889 Isolation Versus Defragmentation: The CHASE-AF Clinical Trial. *J Am Coll Cardiol* 2015;
890 **66**: 2743-2752.

891 [47] Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017
892 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical
893 ablation of atrial fibrillation. *Heart Rhythm* 2017; **14**: e275-e444.

894 [48] Grace A, Verma A, Willems S. Dipole Density Mapping of Atrial Fibrillation. *Eur Heart*
895 *J* 2017; **38**: 5-9.

896 [49] Grace A, Willems S, Meyer C, Verma A, Heck P, Zhu M, et al. High-resolution noncontact
897 charge-density mapping of endocardial activation. *JCI Insight* 2019; **4**.

898 [50] Shi R, Parikh P, Chen Z, Angel N, Norman M, Hussain W, et al. Validation of Dipole
899 Density Mapping During Atrial Fibrillation and Sinus Rhythm in Human Left Atrium. *JACC*
900 *Clin Electrophysiol* 2020; **6**: 171-181.

901 [51] Earley MJ, Abrams DJ, Sporton SC, Schilling RJ. Validation of the noncontact mapping
902 system in the left atrium during permanent atrial fibrillation and sinus rhythm. *J Am Coll*
903 *Cardiol* 2006; **48**: 485-491.

904 [52] Allesie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a
905 mechanism of tachycardia. III. The "leading circle" concept: a new model of circus movement
906 in cardiac tissue without the involvement of an anatomical obstacle. *Circ Res* 1977; **41**: 9-18.

907 [53] Kuklik P, Zeemering S, Maesen B, Maessen J, Crijns HJ, Verheule S, et al. Reconstruction
908 of instantaneous phase of unipolar atrial contact electrogram using a concept of sinusoidal
909 recomposition and Hilbert transform. *IEEE Trans Biomed Eng* 2015; **62**: 296-302.

910 [54] Jalife J, Berenfeld O, Mansour M. Mother rotors and fibrillatory conduction: a mechanism
911 of atrial fibrillation. *Cardiovasc Res* 2002; **54**: 204-216.

912 [55] Roney CH, Cantwell CD, Qureshi NA, Chowdhury RA, Dupont E, Lim PB, et al. Rotor
913 Tracking Using Phase of Electrograms Recorded During Atrial Fibrillation. *Ann Biomed Eng*
914 2017; **45**: 910-923.

915 [56] Berenfeld O, Oral H. The quest for rotors in atrial fibrillation: different nets catch different
916 fishes. *Heart Rhythm* 2012; **9**: 1440-1441.

917 [57] Haissaguerre M, Hocini M, Denis A, Shah AJ, Komatsu Y, Yamashita S, et al. Driver
918 domains in persistent atrial fibrillation. *Circulation* 2014; **130**: 530-538.

919 [58] Swarup V, Baykaner T, Rostamian A, Daubert JP, Hummel J, Krummen DE, et al.
920 Stability of rotors and focal sources for human atrial fibrillation: focal impulse and rotor
921 mapping (FIRM) of AF sources and fibrillatory conduction. *J Cardiovasc Electrophysiol* 2014;
922 **25**: 1284-1292.

923 [59] Ravelli F, Mase M. Computational mapping in atrial fibrillation: how the integration of
924 signal-derived maps may guide the localization of critical sources. *Europace* 2014; **16**: 714-
925 723.

926 [60] Botteron GW, Smith JM. A technique for measurement of the extent of spatial
927 organization of atrial activation during atrial fibrillation in the intact human heart. *IEEE Trans*
928 *Biomed Eng* 1995; **42**: 579-586.

929 [61] Castells F, Cervigon R, Millet J. On the preprocessing of atrial electrograms in atrial
930 fibrillation: understanding Botteron's approach. *Pacing Clin Electrophysiol* 2014; **37**: 133-143.

931 [62] Everett THt, Kok LC, Vaughn RH, Moorman JR, Haines DE. Frequency domain
932 algorithm for quantifying atrial fibrillation organization to increase defibrillation efficacy.
933 *IEEE Trans Biomed Eng* 2001; **48**: 969-978.

934 [63] Lin YJ, Tsao HM, Chang SL, Lo LW, Hu YF, Chang CJ, et al. Role of high dominant
935 frequency sites in nonparoxysmal atrial fibrillation patients: insights from high-density
936 frequency and fractionation mapping. *Heart Rhythm* 2010; **7**: 1255-1262.

937 [64] Gadenz L, Hashemi J, Shariat MH, Gula L, Redfearn DP. Clinical Role of Dominant
938 Frequency Measurements in Atrial Fibrillation Ablation - A Systematic Review. *J Atr*
939 *Fibrillation* 2017; **9**: 1548.

940 [65] Verma A, Lakkireddy D, Wulffhart Z, Pillarisetti J, Farina D, Beardsall M, et al.
941 Relationship between complex fractionated electrograms (CFE) and dominant frequency (DF)
942 sites and prospective assessment of adding DF-guided ablation to pulmonary vein isolation in
943 persistent atrial fibrillation (AF). *J Cardiovasc Electrophysiol* 2011; **22**: 1309-1316.

944 [66] Atienza F, Almendral J, Jalife J, Zlochiver S, Ploutz-Snyder R, Torrecilla EG, et al. Real-
945 time dominant frequency mapping and ablation of dominant frequency sites in atrial fibrillation
946 with left-to-right frequency gradients predicts long-term maintenance of sinus rhythm. *Heart*
947 *Rhythm* 2009; **6**: 33-40.

948 [67] Atienza F, Almendral J, Ormaetxe JM, Moya A, Martinez-Alday JD, Hernandez-Madrid
949 A, et al. Comparison of radiofrequency catheter ablation of drivers and circumferential
950 pulmonary vein isolation in atrial fibrillation: a noninferiority randomized multicenter
951 RADAR-AF trial. *J Am Coll Cardiol* 2014; **64**: 2455-2467.

952 [68] Weber FM, Schilling C, Seemann G, Luik A, Schmitt C, Lorenz C, et al. Wave-direction
953 and conduction-velocity analysis from intracardiac electrograms--a single-shot technique.
954 *IEEE Trans Biomed Eng* 2010; **57**: 2394-2401.

955 [69] Anter E, Duytschaever M, Shen CY, Strisciuglio T, Leshem E, Contreras-Valdes FM, et
956 al. Activation Mapping With Integration of Vector and Velocity Information Improves the
957 Ability to Identify the Mechanism and Location of Complex Scar-Related Atrial Tachycardias.
958 *Circ-Arrhythmia Electrophysiol* 2018; **11**.

959 [70] Dallet C, Roney C, Martin R, Kitamura T, Puyo S, Duchateau J, et al. Cardiac Propagation
960 Pattern Mapping With Vector Field for Helping Tachyarrhythmias Diagnosis With Clinical
961 Tridimensional Electro-Anatomical Mapping Tools. *Ieee T Bio-Med Eng* 2019; **66**: 373-382.

962 [71] Coveney S, Corrado C, Roney CH, Wilkinson RD, Oakley JE, Lindgren F, et al.
963 Probabilistic Interpolation of Uncertain Local Activation Times on Human Atrial Manifolds.
964 *Ieee T Bio-Med Eng* 2020; **67**: 99-109.

965 [72] van Schie MS, Starreveld R, Bogers A, de Groot NMS. Sinus rhythm voltage
966 fingerprinting in patients with mitral valve disease using a high-density epicardial mapping
967 approach. *Europace* 2021; **23**: 469-478.

968 [73] Ganesan AN, Kuklik P, Lau DH, Brooks AG, Baumert M, Lim WW, et al. Bipolar
969 Electrogram Shannon Entropy at Sites of Rotational Activation Implications for Ablation of
970 Atrial Fibrillation. *Circ-Arrhythmia Electrophysiol* 2013; **6**: 48-57.

971 [74] Cuculich PS, Wang Y, Lindsay BD, Faddis MN, Schuessler RB, Damiano RJ, Jr., et al.
972 Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation
973 patterns. *Circulation* 2010; **122**: 1364-1372.

974 [75] Shah AJ, Hocini M, Xhaet O, Pascale P, Roten L, Wilton SB, et al. Validation of novel 3-
975 dimensional electrocardiographic mapping of atrial tachycardias by invasive mapping and
976 ablation: a multicenter study. *J Am Coll Cardiol* 2013; **62**: 889-897.

977 [76] Salinet J, Molero R, Schlindwein FS, Karel J, Rodrigo M, Rojo-Álvarez JL, et al.
978 Electrocardiographic Imaging for Atrial Fibrillation: A Perspective From Computer Models
979 and Animal Experiments to Clinical Value. *Front Physiol* 2021; **12**.

980 [77] Ramanathan C, Ghanem RN, Jia P, Ryu K, Rudy Y. Noninvasive electrocardiographic
981 imaging for cardiac electrophysiology and arrhythmia. *Nat Med* 2004; **10**: 422-428.

982 [78] Bear LR, LeGrice IJ, Sands GB, Lever NA, Loisel DS, Paterson DJ, et al. How Accurate
983 Is Inverse Electrocardiographic Mapping? A Systematic In Vivo Evaluation. *Circ Arrhythm*
984 *Electrophysiol* 2018; **11**: e006108.

985 [79] Duchateau J, Sacher F, Pambrun T, Derval N, Chamorro-Servent J, Denis A, et al.
986 Performance and limitations of noninvasive cardiac activation mapping. *Heart Rhythm* 2019;
987 **16**: 435-442.

988 [80] Dubois R, Shah AJ, Hocini M, Denis A, Derval N, Cochet H, et al. Non-invasive cardiac
989 mapping in clinical practice: Application to the ablation of cardiac arrhythmias. *J*
990 *Electrocardiol* 2015; **48**: 966-974.

991 [81] Schuler S, Potyagaylo D, Dossel O. ECG Imaging of Simulated Atrial Fibrillation:
992 Imposing Epi-Endocardial Similarity Facilitates the Reconstruction of Transmembrane
993 Voltages. *Comput Cardiol Conf* 2017; **44**.

994 [82] Boyle PM, Hakim JB, Zahid S, Franceschi WH, Murphy MJ, Vigmond EJ, et al.
995 Comparing Reentrant Drivers Predicted by Image-Based Computational Modeling and
996 Mapped by Electrocardiographic Imaging in Persistent Atrial Fibrillation. *Front Physiol* 2018;
997 **9**: 414.

998 [83] Haissaguerre M, Hocini M, Shah AJ, Derval N, Sacher F, Jais P, et al. Noninvasive
999 panoramic mapping of human atrial fibrillation mechanisms: a feasibility report. *J Cardiovasc*
1000 *Electrophysiol* 2013; **24**: 711-717.

1001 [84] Vijayakumar R, Vasireddi SK, Cuculich PS, Faddis MN, Rudy Y. Methodology
1002 Considerations in Phase Mapping of Human Cardiac Arrhythmias. *Circ Arrhythm*
1003 *Electrophysiol* 2016; **9**.

1004 [85] Coll-Font J, Dhamala J, Potyagaylo D, Schulze WH, Tate JD, Guillem MS, et al. The
1005 Consortium for Electrocardiographic Imaging. *Comput Cardiol (2010)* 2016; **43**: 325-328.

1006 [86] Sirish P, Li N, Timofeyev V, Zhang XD, Wang L, Yang J, et al. Molecular Mechanisms
1007 and New Treatment Paradigm for Atrial Fibrillation. *Circ Arrhythm Electrophysiol* 2016; **9**.

1008 [87] Nyns ECA, Poelma RH, Volkers L, Plomp JJ, Bart CI, Kip AM, et al. An automated
1009 hybrid bioelectronic system for autogenous restoration of sinus rhythm in atrial fibrillation. *Sci*
1010 *Transl Med* 2019; **11**.

1011 [88] Polina I, Jansen HJ, Li T, Moghtadaei M, Bohne LJ, Liu Y, et al. Loss of insulin signaling
1012 may contribute to atrial fibrillation and atrial electrical remodeling in type 1 diabetes. *Proc Natl*
1013 *Acad Sci U S A* 2020; **117**: 7990-8000.

1014 [89] Hansen BJ, Zhao J, Li N, Zolotarev A, Zakharkin S, Wang Y, et al. Human Atrial
1015 Fibrillation Drivers Resolved With Integrated Functional and Structural Imaging to Benefit
1016 Clinical Mapping. *JACC Clin Electrophysiol* 2018; **4**: 1501-1515.

1017 [90] Boyle PM, Zghaib T, Zahid S, Ali RL, Deng D, Franceschi WH, et al. Computationally
1018 guided personalized targeted ablation of persistent atrial fibrillation. *Nat Biomed Eng* 2019; **3**:
1019 870-879.

1020 [91] Zhao J, Hansen BJ, Wang Y, Csepe TA, Sul LV, Tang A, et al. Three-dimensional
1021 Integrated Functional, Structural, and Computational Mapping to Define the Structural
1022 "Fingerprints" of Heart-Specific Atrial Fibrillation Drivers in Human Heart Ex Vivo. *J Am*
1023 *Heart Assoc* 2017; **6**.

1024 [92] Lee P, Calvo CJ, Alfonso-Almazan JM, Quintanilla JG, Chorro FJ, Yan P, et al. Low-Cost
1025 Optical Mapping Systems for Panoramic Imaging of Complex Arrhythmias and Drug-Action
1026 in Translational Heart Models. *Sci Rep* 2017; **7**: 43217.

1027 [93] Gloschat C, Aras K, Gupta S, Faye NR, Zhang H, Syunyaev RA, et al. RHYTHM: An
1028 Open Source Imaging Toolkit for Cardiac Panoramic Optical Mapping. *Sci Rep* 2018; **8**: 2921.

1029 [94] Kappadan V, Telele S, Uzelac I, Fenton F, Parlitz U, Luther S, et al. High-Resolution
1030 Optical Measurement of Cardiac Restitution, Contraction, and Fibrillation Dynamics in
1031 Beating vs. Blebbistatin-Uncoupled Isolated Rabbit Hearts. *Front Physiol* 2020; **11**: 464.

1032 [95] Lee S, Sahadevan J, Khrestian CM, Markowitz A, Waldo AL. Characterization of Foci
1033 and Breakthrough Sites During Persistent and Long-Standing Persistent Atrial Fibrillation in
1034 Patients: Studies Using High-Density (510-512 Electrodes) Batrial Epicardial Mapping. *J Am*
1035 *Heart Assoc* 2017; **6**.

1036 [96] Teuwen CP, Yaksh A, Lanters EA, Kik C, van der Does LJ, Knops P, et al. Relevance of
1037 Conduction Disorders in Bachmann's Bundle During Sinus Rhythm in Humans. *Circ Arrhythm*
1038 *Electrophysiol* 2016; **9**: e003972.

1039 [97] Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz A, et al. Implant-
1040 based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised
1041 controlled trial. *Lancet* 2014; **384**: 583-590.

1042 [98] Kohno R, Abe H, Oginosawa Y, Tamura M, Takeuchi M, Nagatomo T, et al. Reliability
1043 and characteristics of atrial tachyarrhythmias detection in dual chamber pacemakers. *Circ J*
1044 2011; **75**: 1090-1097.

1045 [99] Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al.
1046 Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med* 2014; **370**: 2478-2486.

1047 [100] Hanke T, Charitos EI, Stierle U, Karluss A, Kraatz E, Graf B, et al. Twenty-four-hour
1048 holter monitor follow-up does not provide accurate heart rhythm status after surgical atrial

1049 fibrillation ablation therapy: up to 12 months experience with a novel permanently implantable
1050 heart rhythm monitor device. *Circulation* 2009; **120**: S177-184.

1051 [101] Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A, et al. Discerning the
1052 incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after
1053 catheter ablation (DISCERN AF): a prospective, multicenter study. *JAMA Intern Med* 2013;
1054 **173**: 149-156.

1055 [102] Kapa S, Epstein AE, Callans DJ, Garcia FC, Lin D, Bala R, et al. Assessing arrhythmia
1056 burden after catheter ablation of atrial fibrillation using an implantable loop recorder: the
1057 ABACUS study. *J Cardiovasc Electrophysiol* 2013; **24**: 875-881.

1058 [103] Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Turov A, Shirokova N, et al.
1059 Use of an implantable monitor to detect arrhythmia recurrences and select patients for early
1060 repeat catheter ablation for atrial fibrillation: a pilot study. *Circ Arrhythm Electrophysiol* 2011;
1061 **4**: 823-831.

1062 [104] Platonov PG, Stridh M, de Melis M, Urban L, Carlson J, Corbucci G, et al. Analysis of
1063 atrial fibrillatory rate during spontaneous episodes of atrial fibrillation in humans using
1064 implantable loop recorder electrocardiogram. *J Electrocardiol* 2012; **45**: 723-726.

1065 [105] Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D, et al.
1066 Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial
1067 fibrillation: Results of the XPECT trial. *Circ Arrhythm Electrophysiol* 2010; **3**: 141-147.

1068 [106] Nolker G, Mayer J, Boldt LH, Seidl K, V VAND, Massa T, et al. Performance of an
1069 Implantable Cardiac Monitor to Detect Atrial Fibrillation: Results of the DETECT AF Study.
1070 *J Cardiovasc Electrophysiol* 2016; **27**: 1403-1410.

1071 [107] Purerfellner H, Pokushalov E, Sarkar S, Koehler J, Zhou R, Urban L, et al. P-wave
1072 evidence as a method for improving algorithm to detect atrial fibrillation in insertable cardiac
1073 monitors. *Heart Rhythm* 2014; **11**: 1575-1583.

1074 [108] Sanders P, Purerfellner H, Pokushalov E, Sarkar S, Di Bacco M, Maus B, et al.
1075 Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac
1076 monitor: Results from the Reveal LINQ Usability Study. *Heart Rhythm* 2016; **13**: 1425-1430.

1077 [109] Mariani JA, Weerasooriya R, van den Brink O, Mohamed U, Gould PA, Pathak RK, et
1078 al. Miniaturized implantable cardiac monitor with a long sensing vector (BIOMONITOR III):
1079 Insertion procedure assessment, sensing performance, and home monitoring transmission
1080 success. *J Electrocardiol* 2020; **60**: 118-125.

1081 [110] Purerfellner H, Sanders P, Sarkar S, Reisfeld E, Reiland J, Koehler J, et al. Adapting
1082 detection sensitivity based on evidence of irregular sinus arrhythmia to improve atrial
1083 fibrillation detection in insertable cardiac monitors. *Europace* 2018; **20**: f321-f328.

1084 [111] Ciconte G, Saviano M, Giannelli L, Calovic Z, Baldi M, Ciaccio C, et al. Atrial
1085 fibrillation detection using a novel three-vector cardiac implantable monitor: the atrial
1086 fibrillation detect study. *Europace* 2017; **19**: 1101-1108.

1087 [112] Schilling C, Keller M, Scherr D, Oesterlein T, Haissaguerre M, Schmitt C, et al. Fuzzy
1088 decision tree to classify complex fractionated atrial electrograms. *Biomed Tech (Berl)* 2015;
1089 **60**: 245-255.

1090 [113] Reich C, Oesterlein, T., Rottmann M, Seemann, Doessel O. Classification of cardiac
1091 excitation patterns during atrial fibrillation. *Current Directions in Biomedical Engineering*
1092 2016; **2**: 161/166.

1093 [114] Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ, et
1094 al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial
1095 fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. *Lancet* 2019;
1096 **394**: 861-867.

1097 [115] Mairesse GH, Moran P, Van Gelder IC, Elsner C, Rosenqvist M, Mant J, et al. Screening
1098 for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document

1099 endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS),
1100 and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE).
1101 *Europace* 2017; **19**: 1589-1623.

1102 [116] Varma N, Cygankiewicz I, Turakhia MP, Heidbuchel H, Hu YF, Chen LY, et al. 2021
1103 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia
1104 Management: Digital Medical Tools for Heart Rhythm Professionals: From the International
1105 Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart
1106 Rhythm Association/Asia-Pacific Heart Rhythm Society. *Circ Arrhythm Electrophysiol* 2021;
1107 **14**: e009204.

1108 [117] Budzianowski J, Hiczkiewicz J, Burchardt P, Pieszko K, Rzezniczak J, Budzianowski P,
1109 et al. Predictors of atrial fibrillation early recurrence following cryoballoon ablation of
1110 pulmonary veins using statistical assessment and machine learning algorithms. *Heart Vessels*
1111 2019; **34**: 352-359.

1112 [118] Furui K, Morishima I, Morita Y, Kanzaki Y, Takagi K, Yoshida R, et al. Predicting long-
1113 term freedom from atrial fibrillation after catheter ablation by a machine learning algorithm:
1114 Validation of the CAAP-AF score. *J Arrhythm* 2020; **36**: 297-303.

1115 [119] Hung M, Hon ES, Lauren E, Xu J, Judd G, Su W. Machine Learning Approach to Predict
1116 Risk of 90-Day Hospital Readmissions in Patients With Atrial Fibrillation: Implications for
1117 Quality Improvement in Healthcare. *Health Serv Res Manag Epidemiol* 2020; **7**:
1118 2333392820961887.

1119 [120] Hung M, Lauren E, Hon E, Xu J, Ruiz-Negron B, Rosales M, et al. Using Machine
1120 Learning to Predict 30-Day Hospital Readmissions in Patients with Atrial Fibrillation
1121 Undergoing Catheter Ablation. *J Pers Med* 2020; **10**.

1122 [121] Li W, Lipsky MS, Hon ES, Su W, Su S, He Y, et al. Predicting all-cause 90-day hospital
1123 readmission for dental patients using machine learning methods. *BDJ Open* 2021; **7**: 1.

- 1124 [122] Alhusseini MI, Abuzaid F, Rogers AJ, Zaman JAB, Baykaner T, Clopton P, et al.
1125 Machine Learning to Classify Intracardiac Electrical Patterns During Atrial Fibrillation:
1126 Machine Learning of Atrial Fibrillation. *Circ Arrhythm Electrophysiol* 2020; **13**: e008160.
- 1127 [123] Shade JK, Ali RL, Basile D, Popescu D, Akhtar T, Marine JE, et al. Preprocedure
1128 Application of Machine Learning and Mechanistic Simulations Predicts Likelihood of
1129 Paroxysmal Atrial Fibrillation Recurrence Following Pulmonary Vein Isolation. *Circ Arrhythm*
1130 *Electrophysiol* 2020; **13**: e008213.
- 1131